- From the Analyst's Couch
- Published:
Antibody–drug conjugates
Nature Reviews Drug Discoveryvolume 12, pages259–260 (2013)Cite this article
31kAccesses
23Altmetric
Subjects
Second-generation ADCs
At the forefront of this new wave of ADC development is brentuximab vedotin, a CD30-specific ADC that was approved by the US Food and Drug Administration (FDA) in August 2011 to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. It was developed through a partnership between Millennium (The Takeda Oncology Group) and Seattle Genetics, using the proprietary linker and cytotoxic platform technology of Seattle Genetics. Sales of brentuximab vedotin in the United States were US$136 million (October 2011 to September 2012) in a relatively small patient population.
This is a preview of subscription content,access via your institution
Access options
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Prices may be subject to local taxes which are calculated during checkout
References
Hughes, B. Antibody–drug conjugates for cancer: poised to deliver?Nature Rev. Drug Discov.9, 665–667 (2010).
Lash, A. Antibody–drug conjugates: the next generation of moving parts.START-UP 27 Dec 2011 (Article #2011900259).
Seattle Genetics. 2012 press releases.Seattle Genetics website[online], (2012).
Author information
Authors and Affiliations
Rachel S. Zolot, Satarupa Basu and Ryan P. Million are at Trinity Partners, 675 Third Avenue, 20th Floor, New York, New York 10017, USA.,
Rachel S. Zolot, Satarupa Basu & Ryan P. Million
- Rachel S. Zolot
You can also search for this author inPubMed Google Scholar
- Satarupa Basu
You can also search for this author inPubMed Google Scholar
- Ryan P. Million
You can also search for this author inPubMed Google Scholar
Corresponding authors
Correspondence toRachel S. Zolot orRyan P. Million.
Rights and permissions
About this article
Cite this article
Zolot, R., Basu, S. & Million, R. Antibody–drug conjugates.Nat Rev Drug Discov12, 259–260 (2013). https://doi.org/10.1038/nrd3980
Published:
Issue Date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
